# Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study

> **NCT02249026** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Gauda, Estelle B., M.D.** · enrollment: 40 (estimated)

## Conditions studied

- Drug; Withdrawal Symptoms, Neonatal
- Withdrawal
- Fetus and Newborn Affected by Other Maternal Medication

## Interventions

- **DRUG:** BZDs + opiate exposure treated with BPN
- **DRUG:** Opiates exposure treated with BPN

## Key facts

- **NCT ID:** NCT02249026
- **Lead sponsor:** Gauda, Estelle B., M.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2016-06
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2016-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249026, "Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02249026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*